These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11805722)

  • 21. FTY720: early clinical experience.
    Dragun D; Fritsche L; Boehler T; Peters H; Budde K; Neumayer HH
    Transplant Proc; 2004 Mar; 36(2 Suppl):544S-548S. PubMed ID: 15041403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rejection following donor or recipient preoperative treatment with FTY720 in rat small bowel transplantation.
    Sakagawa T; Kiyochi H; Honda K; Kobayashi N
    Transpl Immunol; 2004 Nov; 13(3):161-8. PubMed ID: 15381198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA; Hricik DE; Brinker K; Grinyo JM; Schena FP;
    Transplantation; 2002 Dec; 74(11):1560-7. PubMed ID: 12490789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FTY720: from bench to bedside.
    Kahan BD
    Transplant Proc; 2004 Mar; 36(2 Suppl):531S-543S. PubMed ID: 15041402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
    Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R
    Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of transplant rejection: are the traditional immunosuppressants good enough?
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):357-63. PubMed ID: 11575705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomolgus monkeys when given alone, with Cyclosporine Neoral or with RAD.
    Quesniaux VF; Menninger K; Kunkler A; Vedrine C; Bernhard M; Hedinger R; Kraus G; Schuurman HJ
    Transpl Immunol; 2000 Nov; 8(3):177-87. PubMed ID: 11147698
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunossupresive drugs in renal transplantation].
    Baczkowska T; Durlik M
    Pol Arch Med Wewn; 2004 Oct; 112 Spec No():99-120. PubMed ID: 15669207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunosuppressive activity of FTY720, sphingosine 1-phosphate receptor agonist: I. Prevention of allograft rejection in rats and dogs by FTY720 and FTY720-phosphate.
    Chiba K; Hoshino Y; Ohtsuki M; Kataoka H; Maeda Y; Matsuyuki H; Sugahara K; Kiuchi M; Hirose R; Adachi K
    Transplant Proc; 2005; 37(1):102-6. PubMed ID: 15808561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients.
    Park SI; Felipe CR; Machado PG; Garcia R; Skerjanec A; Schmouder R; Tedesco-Silva H; Medina-Pestana JO
    Braz J Med Biol Res; 2005 May; 38(5):683-94. PubMed ID: 15917949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720.
    Wijkstrom M; Kenyon NS; Kirchhof N; Kenyon NM; Mullon C; Lake P; Cottens S; Ricordi C; Hering BJ
    Transplantation; 2004 Mar; 77(6):827-35. PubMed ID: 15077021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FTY720 in combination with CsA inhibits islet xenograft rejection: a study in the pig-to-rat model.
    Zhang J; Song Z; Wijkström M; Bari S; Sundberg B; Nava S; Groth CG; Korsgren O; Wennberg L
    Transplant Proc; 2000 Aug; 32(5):1017. PubMed ID: 10936327
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunosuppressive agents in organ transplantation: past, present, and future.
    Hong JC; Kahan BD
    Semin Nephrol; 2000 Mar; 20(2):108-25. PubMed ID: 10746855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients.
    Budde K; L Schmouder R; Nashan B; Brunkhorst R; W Lücker P; Mayer T; Brookman L; Nedelman J; Skerjanec A; Böhler T; Neumayer HH
    Am J Transplant; 2003 Jul; 3(7):846-54. PubMed ID: 12814476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cell phenotype evaluation at various sites after skin transplantation and FTY720 plus sirolimus therapy.
    Lopes CT; Rosin FC; Cordeiro JA; Bueno V
    Transplant Proc; 2010 Mar; 42(2):573-7. PubMed ID: 20304195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FTY720 blocks allograft rejection by homing of lymphocytes in vivo.
    Yuzawa K; Stephkowski SM; Wang M; Kahan BD
    Transplant Proc; 2000 Mar; 32(2):269. PubMed ID: 10715413
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation.
    Tedesco-Silva H; Pescovitz MD; Cibrik D; Rees MA; Mulgaonkar S; Kahan BD; Gugliuzza KK; Rajagopalan PR; Esmeraldo Rde M; Lord H; Salvadori M; Slade JM;
    Transplantation; 2006 Dec; 82(12):1689-97. PubMed ID: 17198261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FTY 720.
    Drugs R D; 1999 Jan; 1(1):78-80. PubMed ID: 10565994
    [No Abstract]   [Full Text] [Related]  

  • 40. FTY720 and cyclosporine: evaluation for a pharmacokinetic interaction.
    Kovarik JM; Schmouder RL; Barilla D; Büche M; Rouilly M; Berthier S; Wang Y; Van Saders C; Mayer T; Gottlieb AB
    Ann Pharmacother; 2004; 38(7-8):1153-8. PubMed ID: 15138297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.